Viking Therapeutics to Present at SVB Securities Global Biopharma Conference

Rhea-AI Summary

Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company, announced that CEO Brian Lian, Ph.D., will present at the SVB Securities Global Biopharma Conference from February 13-16, 2023. The presentation is scheduled for February 15 at 2:20 p.m. Eastern time and will be conducted virtually. Viking focuses on therapies for metabolic and endocrine disorders and has three compounds in clinical trials, including VK2809 for non-alcoholic steatohepatitis (NASH) and VK2735 for various metabolic disorders. The company holds exclusive rights to five therapeutic programs developed from licensed small molecules.

SAN DIEGO, Feb. 7, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the SVB Securities Global Biopharma Conference. The conference will take place February 13-16, 2023.

Details for this presentation are as follows:

• SVB Securities Global Biopharma Conference
  Details: Viking management will deliver a corporate presentation and participate in 1-on-1 meetings
  Conference Dates: February 13-16, 2023
  Presentation Timing: 2:20 p.m. Eastern on Wednesday, February 15, 2023
  Format: Virtual conference

About Viking Therapeutics, Inc.

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. VK2735 is currently being evaluated in a Phase 1 clinical trial. In the rare disease space, the company is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including VK2809 and VK0214, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com. Follow Viking on Twitter @Viking_VKTX.

View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-present-at-svb-securities-global-biopharma-conference-301740168.html

SOURCE Viking Therapeutics, Inc.

FAQ

What is the date and time of Viking Therapeutics' presentation at the SVB Securities Global Biopharma Conference?

The presentation will take place on February 15, 2023, at 2:20 p.m. Eastern time.

Where can I find the presentation by Viking Therapeutics at the SVB Securities Global Biopharma Conference?

The presentation will be available as part of a virtual conference from February 13-16, 2023.

What is the focus of Viking Therapeutics' research?

Viking Therapeutics focuses on developing therapies for metabolic and endocrine disorders.

What clinical trials are currently in progress for VKTX?

Viking has three compounds in clinical trials, including VK2809 for NASH and VK2735 for metabolic disorders.

What is VK2809 and what condition is it being evaluated for?

VK2809 is a selective thyroid hormone receptor beta agonist currently evaluated for non-alcoholic steatohepatitis (NASH) in a Phase 2b study.